Richard Jones

Clinical Trial The clinical role of VeriStrat testing in patients with advanced non e small cell lung cancer considered unfit for first-line platinum-based chemotherapy *

A. Hackshaw, S. Upadhyay, P. Woll, 2019 .

The clinical role of VeriStrat testing in patients with advanced non–small cell lung cancer considered unfit for first-line platinum-based chemotherapy☆

A. Hackshaw, S. Upadhyay, P. Woll, 2019, European journal of cancer.

EAU and NICE guidelines for the diagnosis and management of prostate cancer. How wide is the channel?

P. Cornford, Richard Jones, 2018 .

Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial.

R. Arriagada, C. Faivre-Finn, S. Senan, 2009, The Lancet. Oncology.

Metastases to breast from primary lung cancer.

F. Roberts, R. Milroy, D. Hansell, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comorbidities in lung cancer: prevalence, severity and links with socioeconomic status and treatment

M. Nicolson, D. McMillan, D. Grose, 2014, Postgraduate Medical Journal.

The impact of comorbidity upon determinants of outcome in patients with lung cancer.

Derek Grose, Marianne Nicolson, Graham Devereux, 2015, Lung cancer.

Variation in Comorbidity and Clinical Management in Patients Newly Diagnosed with Lung Cancer in Four Scottish Centers

M. Nicolson, D. Grose, G. Devereux, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

C. Boshoff, A. Hackshaw, S. Upadhyay, 2012, The Lancet. Oncology.

Simple and Objective Prediction of Survival in Patients with Lung Cancer: Staging the Host Systemic Inflammatory Response

M. Nicolson, D. McMillan, D. Grose, 2014, Lung cancer international.

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

C. Boshoff, A. Hackshaw, S. Upadhyay, 2012, The Lancet. Oncology.